Comparison of neoadjuvant nab‐paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma

This study aimed to compare the feasibility of nab‐paclitaxel plus platinum‐based chemotherapy (nabTP) versus paclitaxel plus platinum‐based chemotherapy (TP) with immune checkpoint inhibitors (ICIs) as a neoadjuvant modality for locally resectable esophageal squamous cell carcinoma (ESCC).

[1]  Xiaolong Yan,et al.  Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE). , 2022, International journal of surgery.

[2]  Bentong Yu,et al.  Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[3]  W. Liang,et al.  Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): A multicenter, phase 2 study , 2022, International journal of cancer.

[4]  Minghui He,et al.  Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma , 2022, Journal for ImmunoTherapy of Cancer.

[5]  OUP accepted manuscript , 2022, The Oncologist.

[6]  H. Deng,et al.  Dexamethasone enhances the lung metastasis of breast cancer via a PI3K-SGK1-CTGF pathway , 2021, Oncogene.

[7]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[8]  E. D. Geijsen,et al.  Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT) , 2021, Clinical Cancer Research.

[9]  Yuyan Zheng,et al.  Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). , 2020, European journal of cancer.

[10]  Sung-Bae Kim,et al.  Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Taube,et al.  Neoadjuvant checkpoint blockade for cancer immunotherapy , 2020, Science.

[12]  Sung-Bae Kim,et al.  Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. , 2019, The Lancet. Oncology.

[13]  Quan P. Ly,et al.  Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  C. Blank,et al.  The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment , 2019, Clinical Cancer Research.

[15]  M. Shah,et al.  KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. , 2019, Future oncology.

[16]  Sung-Bae Kim,et al.  Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study , 2019, JAMA oncology.

[17]  E. Oki,et al.  Neoadjuvant Chemotherapy Versus Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma , 2018, AntiCancer Research.

[18]  R. Cerfolio,et al.  Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Ismail,et al.  Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. , 2018, Journal of thoracic disease.

[20]  H. Grabsch,et al.  Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial , 2017, The Lancet. Oncology.

[21]  W. Mao,et al.  Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma , 2016, Oncotarget.

[22]  H. Loong,et al.  Evolving Evidence of the Efficacy and Safety of nab-Paclitaxel in the Treatment of Cancers with Squamous Histologies , 2016, Journal of Cancer.

[23]  E. Steyerberg,et al.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. , 2015, The Lancet. Oncology.

[24]  J. Bosset,et al.  Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Hill,et al.  Association between preoperative glucocorticoids and long-term survival and cancer recurrence after colectomy: follow-up analysis of a previous randomized controlled trial. , 2014, British journal of anaesthesia.

[26]  W. Mao,et al.  A phase II study of weekly nab-paclitaxel in combination with cisplatin as neoadjuvant chemotherapy in patients (pts) with locally advanced esophageal squamous cell carcinoma (SCC). , 2014 .

[27]  Yan Shi,et al.  Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma , 2013, OncoTargets and therapy.

[28]  M. Socinski,et al.  Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[30]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Shahin,et al.  A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. , 2011, Gynecologic oncology.

[32]  V. Gebski,et al.  Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. , 2011, The Lancet. Oncology.

[33]  R. McWilliams,et al.  A phase II trial of nab‐paclitaxel (ABI‐007) and carboplatin in patients with unresectable stage IV melanoma , 2011, Cancer.

[34]  M. Flister,et al.  Synergy of nab-paclitaxel and bevacizumab in eradicating large orthotopic breast tumors and preexisting metastases. , 2011, Neoplasia.

[35]  P. Siersema,et al.  Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: Long-term results of a randomized controlled trial , 2011, BMC Cancer.

[36]  Karin Haustermans,et al.  Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. , 2010, The Lancet. Oncology.

[37]  J. Lv,et al.  Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. , 2010, World journal of gastroenterology.

[38]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  D. Girling.  Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial , 2002, The Lancet.